




María J. Moreno*, Marguerite Ball*,
Marina Rukhlova*, Jacqueline Slinn*,
Denis L’Abbe†, Umar Iqbal*, Robert Monette*,
Martin Hagedorn‡,§,MaureenD.O’Connor-McCourt†,
Yves Durocher† and Danica B. Stanimirovic*
*National Research Council of Canada, Ottawa, Ontario,
Canada; †National Research Council of Canada, Montreal,
Quebec, Canada; ‡University of Bordeaux, LAMC, UMR
1029, Talence, France; §INSERM, LAMC, UMR 1029,
Talence, France
Abstract
Insulin-like growth factor–binding protein 4 (IGFBP-4/IBP-4) has potent IGF-independent anti-angiogenic and anti-
tumorigenic effects. In this study, we demonstrated that these activities are located in the IGFBP-4 C-terminal
protein fragment (CIBP-4), a region containing a thyroglobulin type 1 (Tg1) domain. Proteins bearing Tg1 domains
have been shown to inhibit cathepsins, lysosomal enzymes involved in basement membrane degradation and
implicated in tumor invasion and angiogenesis. In our studies, CIBP-4 was shown to internalize and co-localize
with lysosomal-like structures in both endothelial cells (ECs) and glioblastoma U87MG cells. CIBP-4 also inhibited
both growth factor–induced EC tubulogenesis in Matrigel and the concomitant increases in intracellular cathepsin
B (CatB) activity. In vitro assays confirmed CIBP-4 capacity to block recombinant CatB activity. Biodistribution anal-
ysis of intravenously injected CIBP-4–Cy5.5 in a glioblastoma tumor xenograft model indicated targeted accumu-
lation of CIBP-4 in tumors. Most importantly, CIBP-4 reduced tumor growth in this animal model by 60%.
Pleiotropic anti-angiogenic and anti-tumorigenic activities of CIBP-4 most likely underlie its observed therapeutic
potential against glioblastoma.
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Introduction
The insulin-like growth factor–binding protein (IGFBP) family
comprises six related protein members (IGFBP-1 to IGFBP-6) that
exhibit high affinity for IGF-1 and IGF-2 [1]. IGFBPs function as
carriers of IGFs, prolonging their half-lives and modulating their
biologic functions in target cells [1]. In circulation and interstitial
fluids, IGFs are tightly associated with IGFBPs and released only
after IGFBP proteolysis; this allows the binding of IGFs to plasma
membrane IGF receptors through which they exert multiple biologic
actions including stimulation of cell proliferation, differentiation,
migration, survival, and angiogenesis [2,3]. IGFBPs inhibit these
actions by sequestering IGFs away from the receptors. However, some
IGFBP members possess heparin-binding domains (HBDs) that facil-
itate the interaction of the protein with heparin sulfate proteoglycans
of the extracellular matrix (ECM), increasing IGF concentration in
the proximity of the receptors and thereby enhancing IGF activities
[4–6]. In addition, some IGFBPs also have IGF-independent biologic
activities [7], although the mechanism(s) of action involved in these
specific functions are still not clearly understood.
The IGFBP mature forms are all secreted proteins. IGFBP-4/IBP-4
is the smallest of the six members [8] and can be found both in non-
glycosylated (24 kDa) and N-glycosylated (28 kDa) forms [9]. We
have previously reported [10] that IGFBP-4 inhibits angiogenesis
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and glioblastoma tumor growth in vitro. The anti-angiogenic effect of
IGFBP-4 was pleiotropic against multiple angiogens, including IGF-1,
vascular endothelial growth factor (VEGF), placenta growth factor, and
basic fibroblast growth factor. These inhibitory effects of IGFBP-4
were recently confirmed by Contois et al. [11] using the chick chorio-
allantoic membrane (CAM) angiogenesis model. In addition, our
studies indicated that the anti-tumorigenic effect of IGFBP-4 in
the human glioblastoma cell line U87MG is IGF-independent
[10]. However, the mechanisms governing these IGF-independent
inhibitory effects of IGFBP-4 are not fully understood.
The six IGFBP family members share a highly conserved structure
with threemajor domains, namely,N-terminal domain, central domain,
and C-terminal domain, each containing specific subdomains or
functional motifs [1]. The N-terminal domain contains important
IGF-binding residues that allow for the high-affinity binding of IGF
to IGFBPs. The central domain does not exhibit structural similarities
among the IGFBP family members; however, sites of N-linked and
O-linked glycosylation as well as other sites of posttranslational modi-
fication are found in this region [1]. The C-terminal domain contains a
thyroglobulin type 1 (Tg1) subdomain; this protein module is present
in a number of structurally and functionally unrelated proteins such
as thyroglobulin, equistatin, saxiphilin, nidogen, testican-1, the major
histocompatability complex (MHC) class II–associated invariant chain,
and secretedmodular calcium-binding proteins (SMOCs) [12]. Although
the role of Tg1 domains has not been fully elucidated yet, the ability of
some Tg1 domain–containing proteins to inhibit proteases, primarily
cysteine cathepsins, suggests that Tg1 domains may represent a novel
group of protease inhibitors [13].
Cathepsins are a large family of proteolytic enzymes responsible
for intracellular protein processing and degradation in normal cells.
They also play important roles in bone remodeling, epidermal homeo-
stasis, and antigen presentation [14]. Emerging evidence indicates that
they are also pivotal players in cancer progression, angiogenesis, and
metastasis [15]. Cysteine cathepsins are typically localized in lysosomes
and other intracellular compartments; however, in tumors and other
activated cells, cathepsins can be translocated to the plasma membrane
and, in some cases, secreted into the extracellular space where they par-
ticipate in the degradation of the ECM components such as laminin,
fibronectin, tenascin C, and type IV collagen [16–18], facilitating tumor
cell migration and invasion [16,18]. Cathepsins have also been impli-
cated in the activation of other enzymes of the proteolytic cascade that
mediate ECMdegradation, such asmatrixmetalloproteases (MMPs) and
urokinase plasminogen activator [19]. The human cysteine cathepsin
family comprises 11 members (B, C, H, F, K, L, O, S, V, W, and X/Z).
Cathepsin B (CatB) specifically has been linked to glioma invasiveness
[20] and angiogenesis [21,22] and is a prognostic factor for survival in
patients with brain tumors [23].
As previously indicated, the N-terminal sequence of IGFBP-4
contains an IGF-binding domain that is most likely responsible for
its IGF-dependent actions. To investigate the IGF-independent mecha-
nisms underlying the anti-angiogenic and anti-tumorigenic effects of
IGFBP-4, we focused this study on the C-terminal sequence [IGFBP-4
C-terminal protein fragment (CIBP-4)] that contains a Tg1 domain.
We produced recombinant CIBP-4 and demonstrated that this poly-
peptide retains the pleiotropic anti-angiogenic and anti-tumorigenic
properties previously identified in the full-length IGFBP-4 protein.
Furthermore, we showed that these effects are associated with its potent
anti-CatB activity and that CIBP-4 significantly reduces tumor growth
in a xenograft glioblastoma tumor model.
Materials and Methods
Production of Recombinant Full-Length IGFBP-4
and CIBP-4
Full-length IGFBP-4 (IBP-4, Accession number BC016041; MGC:
20162) was amplified with forward (F1: 5′-TAAGAATTCGCCAC-
CATGCTGCCCCTCTGCCT-3′) and reverse (R1: 5′-TTAGGA
TCCACCTCTCGAAAGCTGTCAGCC-3′) primers, digested with
EcoRI and BamHI (New England Biolabs, Whitby, Ontario) and
cloned in-frame into pTT5SH8Q1 expression plasmid (a smaller
version of pTTSH8Q1 vector) containing the C-terminal Steptag-II/
(His)8GGQ dual tags [24,25]. The IGFBP-4 C-terminal domain
(CIBP-4; nt 155–258) was amplified with forward (F2: 5′-GCCG
CTAGCAAGGTCAATGGGGCGCCCCGGGA-3′) and reverse
(R1) primers, digested with NheI and BamHI and ligated in-frame into
pYD1 plasmid (pTT5SH8Q1 vector with secreted alkaline phospha-
tase (SEAP) signal peptide MLLLLLLLGLRLQLSLGIA). Cells were
transfected essentially as described [26] with the following modifica-
tions: HEK293-6E cells (293-EBNA1 clone 6E) growing as suspension
cultures in FreeStyle F17 medium (Life Technologies, Burlington,
Ontario) were transfected at 1 × 106 cells/ml. A feed with 0.5% (wt/vol)
TN1 peptone (TekniScience, Terrebonne, Quebec) was done 24 hours
post-transfection [27]. Culture media were harvested 120 hours post-
transfection and IGFBP-4 constructs were purified by sequential affinity
chromatography on Fractogel EMD-chelate (EMD-Millipore, Billerica,
MA) charged with cobalt [28] followed by StrepTactin-Sepharose as
previously described [24]. Purified material was desalted in phosphate-
buffered saline (PBS) on D-Salt Excellulose columns (Pierce, Thermo
Scientific, Nepean, Ontario) as recommended by the manufacturer.
For large-scale CIBP-4 production for animal studies, a 293-6E pool
stably expressing CIBP-4 was generated using the pYD7 vector [29]
encodingCIBP-4 containing the SEAP single peptide and theC-terminal
Steptag-II/(His)8GGQ dual tag (see above). The pool was obtained
following transfection of 293-6E cell with pYD7/CIBP-4 plasmid
and selection with 5 μg/ml blasticidin (InvivoGen, San Diego, CA)
for 3 weeks and 2 μg/ml for another 2 weeks until cells recovered from
selection. Blasticidin concentration was then reduced to 0.5 μg/ml for
routine cell maintenance. Large-scale CIBP-4 productions were
achieved in 10-l or 20-l WAVE bioreactor (GE Healthcare Life
Sciences, Baie d’Urfé, Quebec) in F17 medium at 37°C using the
manufacturer’s recommended conditions. Wave bags were inoculated
at 2 × 105 cells/ml and a 0.5% (wt/vol) TN1 feed was performed 3 days
post-inoculation. The cultures were typically harvested 8 days post-
inoculation (typical cell viability >80%), cells were removed by centri-
fugation, and clarified medium was concentrated by tangential flow
filtration using a 3-kDa Centrasette membrane (Pall Corporation,
Mississauga, Ontario). CIBP-4 in the concentrated medium was puri-
fied on Fractogel-cobalt as described previously [28] and formulated in
PBS. Protein concentration was determined by absorbance at 280 nm
using CIBP-4 molar extinction coefficient.
Cell Cultures
Human brain endothelial cells (HBECs) were obtained from small
intracortical microvessels and capillary fractions (20–112 μm) har-
vested from human temporal cortex excised surgically from patients
treated for idiopathic epilepsy. Tissues were obtained with approval
from the Montreal Neurological Institute Research Ethics Committee.
Briefly, cortices were homogenized in Dulbecco’s modified Eagle’s
medium (DMEM) and filtered through a series of Nitex meshes (Sefar
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Canada, Saint-Laurent, Quebec) of 350-, 112-, and 20-μm sizes.
Vessels from 20-μm mesh were pelleted, digested with collagenase IV
(1 mg/ml; Sigma-Aldrich, St Louis, MO) in DMEM (Wisent,
St Jean-Baptiste, Quebec) for 5 minutes, and collected by centrifuga-
tion. Vessels were then resuspended in media containing DMEM
high glucose, 5% heat-inactivated human serum (Sigma-Aldrich),
10% heat-inactivated FBS (HyClone, Logan, UT), 20% medium
conditioned murine melanoma cells (mouse melanoma, Cloudman
S91, clone M-3, melanin-producing cells purchased from ATCC,
Manassas, VA), 5 μg/ml endothelial cell growth supplement (ECGS),
insulin-transferrin-selenium premix (final concentrations: 5 μg/ml insu-
lin, 5 μg/ml transferrin, 5 ng/ml selenium; BD Biosciences, Bedford,
MA), and 5 units/ml heparin (Sigma-Aldrich), plated on 0.5% gelatin-
coated plastic (Sigma-Aldrich) and grown at 37°C in 5% CO2/95% air.
Media were replaced on a 3-day cycle. HBECs were separated from
smooth muscle cells with cloning rings at days 10 to 14. Cells were
trypsinized weekly at 1:3 split ratio for 8 to 12 passages. HBEC cultures
were routinely characterized morphologically and biochemically. More
than 95% of cells in culture stained immunopositive for the selective
endothelial markers, angiotensin II–converting enzyme and factor
VIII–related antigen, incorporated fluorescently labeled acetylated
low-density lipoprotein, and exhibited high activities of the blood-
brain barrier–specific enzymes, γ-glutamyltranspeptidase and alkaline
phosphatase [30].
The human glioma cell line U87MG was derived from human
patients diagnosed with grade III astrocytoma and obtained from
ATCC. Cells (5 × 104 cells/ml) were plated in poly-L-lysine (25 μg/ml;
Sigma-Aldrich) precoated 35-mm dishes and grown at 37°C in DMEM
containing 10% FBS (HyClone) in humidified atmosphere of 5%
CO2/95% air. To obtain U87MG conditioned media (CM), cells were
grown to 80% confluence in growth media and replaced by serum-free
DMEM for 3 days, collected, and filtered (Millex-GV sterilizing filter
unit, 0.22 μm; Millipore, Etobicoke, Ontario).
Capillary-like Tube Formation Assay and Intracellular
CatB Activity Measurement
In vitro angiogenesis was assessed by endothelial tube formation in
a growth factor–reduced basement membrane, Matrigel (BD Bio-
sciences), as previously described [10]. Twenty-four–well plates were
coated with 300 μl of unpolymerized Matrigel (7–11 mg protein/ml,
diluted 1:2 in DMEM) and allowed to polymerize for 30 minutes at
37°C. HBECs (4 × 104) were suspended in 500 μl of DMEM alone,
DMEM containing growth factors (150 ng/ml IGF-I or 20 ng/ml
VEGF165; R&D Systems, Minneapolis, MN), or U87MG CM
(as described in Cell Cultures section) in the absence or presence
of 20 nM IBP-4 or CIBP-4 and plated into Matrigel-coated wells.
Capillary-like tube (CLT) formation was analyzed after 24 hours using
an Olympus 1X50 microscope. Phase contrast images were captured
using a digital video camera (Olympus U-CMT) and analyzed with
Northern Eclipse v.5.0 software. Grayscale images were thresholded,
converted to binary images, and skeletonized, and the total length
and number of nodes (branching points) of the CLT formed by
HBECs were quantified. Experiments were performed in duplicate
wells and repeated at least four times. To determine the levels of CatB
activity in each experimental condition, 260× dilutionMagic Red CatB
reagent (Immunochemistry Technologies, Bloomington, MN) was
added to all wells at the end of the experiment and maintained at
37°C in the dark for 2 hours. Magic Red contains a membrane per-
meable CatB target sequence peptide (arginine-arginine) linked to an
amide-substituted fluorophore, cresyl violet, that upon enzymatic
cleavage at the arginine amide linkage site generates red fluorescence.
Cells were washed twice with Hank’s balanced salt solution (HBSS)
and intracellular fluorescence quantification (530-nm excitation and
645-nm emission) was performed using a cytofluorimeter plate reader
(Bio-Tek FL600; BioTek Instruments, Inc, Winooski, VT).
In Vitro Evaluation of CatB Activity
The ability of CIBP-4 to inhibit the catalytic activity of a recom-
binant human CatB (rhCatB) enzyme expressed in the NSO murine
myeloma cell line (R&D Systems) was evaluated using the fluoro-
genic peptide substrate, N -carbobenzyloxy-Leu-Arg-7-amido-4-
methylcoumarin (Z-L-R-AMC; R&D Systems). rhCatB (10 μg/ml)
was activated by preincubation in 25 mM 2-(N -morpholino)ethane-
sulfonic acid (JT Baker, Phillipsburg, NJ) and 5 mM DL-dithiothreitol
(Sigma-Aldrich) at pH 5.0 for 15 minutes at room temperature. Active
rhCatB (10 ng) alone or in the presence of either CIBP-4 (0.1–10 μM)
or the synthetic CatB inhibitor Ca-074 ME (0.1–10 μM; Calbiochem,
La Jolla, CA) was added to Z-L-R-AMC (50 μM) in 25 mM 2-
(N -morpholino)ethanesulfonic acid (pH 5.0). Fluorescence released
by the cleavage of Z-L-R-AMC was measured at 37°C every 5 minutes
for a total of 60 minutes using a cytofluorimeter plate reader with
excitation and emission wavelengths of 380 and 460 nm, respectively.
Anchorage-dependent and Anchorage-Independent U87MG
Cell Growth
Anchorage-dependent U87MG cell growth was evaluated using
the CyQUANT Cell Proliferation Assay Kit (Molecular Probes,
Eugene, OR) following the manufacturer’s protocol as previously
described [31]. HBECs were plated in quadruplicate in 96-well
plates at a density of 3000 cells/well. Cells were grown in phenol
red–free DMEM (Life Technologies) + 1% FBS alone or in the pres-
ence of 20 nM IBP-4, 20 nM CIBP-4, or 500 μM dibutyryladenosine
cyclic monophosphate (dB-cAMP; positive control; Sigma-Aldrich).
Treatments were reapplied at day 3. Plates were harvested at 2, 3, 5,
and 6 days by gently removing media, blotting the microplates dry,
and storing at −80°C until analysis. Plates were thawed at 21°C and
200 μl of CyQUANT GR dye/lysis buffer was added to each well
for 5 minutes in the dark. Fluorescence values were measured using
a cytofluorimeter plate reader at 485-nm excitation and 530-nm
emission, and cell numbers were derived from a standard curve.
Experiments were repeated three times.
Anchorage-independent U87MG cell growth was evaluated in
semisolid agar in the absence or presence of either 20 nM IBP-4 or
CIBP-4 as described previously [10]. Approximately 1800 cells ±
treatment were resuspended in 150 μl of growth medium (DMEM +
10% FBS) containing 0.6% agar (Quelab, Montreal, Quebec) and
seeded into a well of a 24-well plate previously layered with 250 μl
of 0.6% agar. The solidified cell layer was covered with 50 μl of
DMEM ± treatment that was replaced every 3 days over a 14-day
period. Phase contrast images (six fields per well) were captured using
a digital video camera (Olympus U-CMT) and analyzed with Northern
Eclipse v.5.0 software. Color images were transformed to grayscale,
thresholded, and then converted to binary images. Number and area
of colonies per field were calculated. To measure cell viability, at the
end of the experiment, 50 μl of Alamar Blue (Cedarlane, Burlington,
Ontario) was added to each well and fluorescence readings (530-nm
excitation and 590-nm emission) were performed every 10 minutes
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for a period of 180 minutes. Experiments were repeated four times
in triplicates.
Conjugation of Alexa Fluor 647 to IGFBP-4 and
CIBP-4 Protein Fragments
Eighty microliters of 1 mM Alexa Fluor 647 (AF647) succini-
midyl ester (Molecular Probes) in DMSO was added to 0.4 ml of
0.2 mg/ml IBP-4 or CIBP-4 recombinant proteins in 100mM carbonate
(pH 8.4), and samples were incubated overnight at room tempera-
ture. The reactions were stopped with 150 μl of 200 mM ethanol-
amine (pH 8.0). To remove free AF647 dye, samples were diluted
with 4.5 ml of water and loaded onto 1 ml of Co2+-Talon Metal
Affinity column (Pierce, Thermo Scientific) equilibrated with PBS.
The column was exhaustively washed with PBS and the labeled pro-
teins were eluted with 2 ml of 1 M imidazole in PBS. To remove imid-
azole from labeled protein and peptides, the sample was concentrated
to approximately 200 μl on Biomax (molecular weight cutoff, 5000;
Thermo Scientific, Nepean, Ontario), diluted to original volume with
PBS, and concentrated again. The process of concentration/dilution
was repeated three times. The final volume was 0.5 ml (0.14 mg/ml).
Recovery was between 84% and 87%.
Confocal Laser Scanning Microscopy
Internalization of AF647-conjugated CIBP-4 in HBECs and
U87MG cells was analyzed by confocal laser scanning microscopy.
HBECs (30,000) and U87MG (50,000) cells were, respectively,
seeded on human fibronectin (50 μg/ml; BD Biosciences) or poly-
L-lysine–coated coverslips in HBEC or U87MG media at 37°C
and grown to 80% confluence. Cells were washed twice with HBSS
and incubated in DMEM for 15 minutes at 37°C before the addition
of 200 nM AF647–CIBP-4 for up to 4 hours. Images were collected
at 90 minutes after removing the fluorescent peptides by washing the
cells three times with HBSS.
To determine co-localization of the fluorescently tagged peptides
with lysosomes in HBEC, cells were incubated with DMEM con-
taining 200 nM AF647-peptide conjugate and 150 nM LysoTracker
Yellow HCK-123 (Molecular Probes) for 90 minutes and then washed
with HBSS. Cells exposed were counterstained with the membrane dye
Merocyanine 540 (10 μM; Sigma-Aldrich) for 15 minutes and then
washed with HBSS.
To determine whether CIBP-4 can inhibit CatB activity in
U87MG cells, the cells were incubated with DMEM containing
200 nM unlabeled CIBP-4 for 75 minutes, and then 520× dilution
of Magic Red CatB detection solution was added for an additional
15 minutes. The cells were counterstained with the membrane dye
DiOC5(3) (500 nM; Molecular Probes) for 30 seconds and then
washed with HBSS. Imaging of cells was performed using a Zeiss
LSM 410 (Carl Zeiss, Thornwood, NY) inverted laser scanning micro-
scope equippedwith an argon/krypton ion laser and a Plan-Apochromat
63×, NA 1.4. Confocal images of two fluoroprobes were sequentially
obtained using 488-nm excitation and 515- to 540-nm emission
to detect both DiOC5(3) and LysoTracker Yellow HCK-123 fluo-
rescence, 568-nm excitation and 575- to 640-nm emission to detect
bothMerocyanine 540 andMagic Red CatB fluorescence, and 647-nm
excitation and 670- to 810-nm emission to detect AF647 fluorescence.
CAM Experimental Glioma Assay
The ability of CIBP-4 to inhibit glioblastoma tumor growth was
assessed in tumor model in chick embryos (U87MG cell grafted on
the CAM) as previously described [32,33].
Fertilized chicken (Gallus gallus) eggs were obtained from Canadian
Food Inspection Agency and placed into an egg incubator at 37°C and
67% to 70% humidity (day 0). At day 3, windows were cut in the
Figure 1. Production of IBP-4 and CIBP-4 in HEK293 cells. (A) IBP-4 (lane 1; 7.5 μg loaded) and CIBP-4 (lane 2; 3.5 μg loaded) proteins were
generated by large-scale transfection of HEK293 cells and purified by immobilized metal affinity chromatography on Fractogel-cobalt
column, followed by a second affinity purification on StrepTactin-agarose. For large-scale CIBP-4 production for animal studies, a HEK293 pool
stably expressing the protein was generated and grown in 10-l WAVE bioreactor. The secreted CIBP-4 protein was purified by immobilized
metal affinity chromatography only (lane 3; 2.5 μg loaded). Proteins were resolved by reducing sodium dodecyl sulfate–polyacrylamide gel
electrophoresis and stained by Coomassie Blue R-250. (B) Amino acid sequence of IBP-4 and CIBP-4. The signal peptides are underlined,
whereas the Steptag-II/(His)8GGQ tags are italicized. The three amino acids in bold (IAS) shown in CIBP-4 sequence are derived from theSEAP.
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eggshell and covered with protective surgical Durapore tape until
day 10. Then, a sterile plastic ring was placed onto the CAM, the
delimited surface carefully scraped with a scalpel blade, and a pellet
of 106 U87MG cells deposited into the center of the ring. From
days 11 to 14, 30 μl of either 3% DMSO alone (vehicle) or in combina-
tion with 108 ng of CIBP-4 was topically applied over the tumor each
day. At day 17, the tumors were isolated from the CAM and weighed.
Frequency distribution of the tumor population between vehicle-
treated and CIBP-4–treated groups was analyzed for three size inter-
vals using Chi-square test.
Subcutaneous Xenograft Tumor Model
CD-1 nude mice (male, 6–8 weeks old) were purchased from
Charles River Canada (Saint Constant, Quebec). The animals were
housed in cages, in groups of three to five, and maintained on a 12-hour
light/dark schedule with a temperature of 22°C and a relative humidity of
50 ± 5%. Sterilized food and water was available ad libitum. Experi-
ments were approved by the National Research Council Canada
(NRCC) Animal Care Committee in accordance with Canadian
Council on Animal Care guidelines. For subcutaneous tumor implan-
tation, mice underwent light isoflurane anesthesia, and 3 × 106
U87MG tumor cells per 50 μl of Matrigel (dilution 1:1 in saline) were
injected subcutaneously in the left flank of the mice using a 300-μl
syringe. The size of the tumors was monitored with a caliper. Tumor
volume was calculated using the formula (length × width2)/2. When
the tumors reached a volume of ∼100 mm3, initiating the exponential
growth phase, animals were intravascularly (i.v.) administered with
either vehicle or 10 mg/kg CIBP-4 three times per week. Animals were
sacrificed when tumors reached ∼2500 mm3.
In Vivo Near-Infrared Fluorescence Imaging
CIBP-4 was labeled with Cy5.5 succinimidyl ester using methods
recommended by the manufacturer (GE Healthcare, Mississauga,
Ontario). Labeling was optimized to achieve a dye/antibody ratio
of 1. U87MG subcutaneous tumor-bearing animals were i.v injected
(via tail vein) with 100 μg of CIBP-4–Cy5.5 and imaged at multiple
time intervals (0.5, 1, 2, 4, and 24 hours) using a small-animal time-
domain eXplore Optix MX2 Preclinical Imager (Advanced Research
Technologies, Montreal, Quebec) as previously described [34]. In all
imaging experiments, a 670-nm pulsed laser diode with a repetition
frequency of 80 MHz and a time resolution of 12-ps light pulse was
used for excitation. The fluorescence emission at 700 nm was col-
lected by a highly sensitive time-correlated single-photon counting
system and detected through a fast photomultiplier tube. The data
were recorded as temporal point-spread functions and the images were
reconstructed as fluorescence concentration maps using ART Optix
Optiview analysis software 2.0 (Advanced Research Technologies).
At the end of the imaging, animals were injected with 40 μg of
fluorescein-labeled tomato lectin (Vector Laboratories, Burlingame,
CA) to stain blood vessels, then sacrificed 10 minutes later by trans-
cardial perfusion with saline under deep anesthesia. The tumors were
excised and fixed overnight in formalin and then sectioned with a
viibratome (Ted Pella, Redding, CA). Tissue sections were mounted
on Superfrost Plus microscope slides (Fisher Scientific, Nepean,
Ontario) using mounting media containing 2 μg/ml 4′,6-diamidino-
2-phenylindole, dihydrochloride (DAPI) nuclei stain (Sigma-Adrich).
Sections were then visualized under anOlympus 1X 81 invertedmotor-
ized microscope (Olympus, Markham, Ontario). InVivo and ImagePro
6.2 software (Olympus) were used to acquire and analyze images.
Pharmacokinetic Profile of CIBP-4
CIBP-4–Cy5.5 (300 μg) was injected through the tail vein in CD-1
mice and subjected to fluorophore-based pharmacokinetic analysis as
described previously [34]. After CIBP-4–Cy5.5 injection, blood sam-
ples (50 μl) were collected into ice-stored heparin-coated tubes at dif-
ferent time points (0, 0.5, 1, 1.5, 2, and 4 hours) from a small nick
produced in the tail vein. Levels of CIBP-4–Cy5.5 were quantified in
the blood samples using a fluorescent plate reader with 670-nm excita-
tion and 690-nm emission. The concentration of protein in each sample
was derived from standard curves consisting of a range of concentra-
tions of the labeled proteins diluted in mouse blood. Pharmacokinetic
parameters were calculated using the WinNonlin pharmacokinetic
software package version 5.2 (Pharsight Corporation, Sunnyvale, CA).
Figure 2. Effects of IBP-4 and CIBP-4 on growth factor–induced
CLT formation by HBEC grown inMatrigel. Histograms representing
total length (left panels) and number of branching nodes (right
panels) of CLT networks. HBECs were exposed to DMEM, U87MG
CM, 150 ng/ml IGF-1, or 20 ng/ml VEGF in the absence (black bars) or
presence (hatched bars) of either 20 nM IBP-4 or CIBP-4. Bars are
means± SEM of four to seven experiments; * and *** indicates sig-
nificant difference (P < .05 and P < .001, respectively) between
growth factor–treated HBEC in the absence or presence of IBP-4/
CIBP-4. Significancewasdetermined by analysis of variance (ANOVA)
followed by Dunnett’s multiple comparison test.
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A two-compartment IV bolus model was selected for pharmaco-
kinetic modeling, because it best represented the data and route of
administration. This model is described by the following equation: C(t) =
Aexp(−αt) + Bexp(−βt), where C (t) represents the concentration of
agent in serum, A and B represent the zero time intercept of the α phase
and β phase, respectively, and α and β are disposition rate constants,
α > β. The area under the serum concentration–time curve (AUC)
was calculated with the equation AUC0-∞ = D/V /K10, where D
is the dose given, V is the apparent distribution volume, and K10 is
the elimination rate constant. Total clearance was determined from
the equation Cl/F = D/AUC0-∞.
Results
Production of Recombinant IBP-4 and CIBP-4
Protein Fragments
Full-length (IBP-4) and C-terminal (CIBP-4) constructs bearing a
dual C-terminal Streptag-II and polyhistidine tag were expressed in
HEK293 cells and purified by affinity chromatography. The transient
expression of both constructs in HEK293 cells followed by sequential
affinity chromatography on Fractogel-cobalt followed by StrepTactin-
agarose typically generated 5 to 10 mg of purified protein per liter of
culture (Figure 1A, lanes 1 and 2). Due to the large amounts of recom-
binant protein needed for conducting animal studies, we generated a
stable HEK293 pool expressing CIBP-4. From a 10-l batch culture
and following a single Fractogel-cobalt affinity capture, between 200
and 350 mg was typically obtained (Figure 1A, lane 3).
IBP-4 and CIBP-4 Inhibit HBEC CLT Formation
in Matrigel
Angiogenic responses induced by U87MG CM and growth factors
(IGF-1 and VEGF) on HBEC seeded in Matrigel were evaluated by
the total length and the number of nodes/branching points of the
CLT networks formed. A tight correlation in the pattern of changes
between CLT total length (Figure 2, left panels) and number of nodes
(Figure 2, right panels) was obtained for each individual experiment.
HBEC exposed to DMEM showed a variable response ranging
from no angiogenic activity (flat cells, no tubulogenesis) to a restricted
spontaneous angiogenic activity (sprouting with minimal tube forma-
tion and connectivity; Figure 2, A–C ). U87MG CM (Figure 2A) and
the growth factors IGF-1 (Figure 2B) and VEGF165 (Figure 2C ),
respectively, induced ∼2.2-, 1.8-, and 3.6-fold increase in both HBEC
CLT total length and node number compared to DMEM. IBP-4
(20 nM) and CIBP-4 (20 nM) blocked the angiogenic responses
induced byU87MGCMand both growth factors were tested (Figure 2,
A–C ), keeping HBEC responses at spontaneous angiogenic levels.
Figure 3. Effect of CIBP-4 on CatB activity. (A) Histogram repre-
senting the in vitro proteolytic activity of human recombinant CatB
protein (10 ng) in the absence or presence of either CIBP-4 (0.1–
10 μM) or the synthetic CatB inhibitor CA-074 ME (0.1–10 μM).
Bars are means ± SEM of three experiments (n = 9). *P < .05
and **P < .0001 indicates significant difference between active
rhCatB alone or in the presence of the treatments as determined
by ANOVA followed by Dunnett’s multiple comparison test. (B–D)
Representative graphs of a single experiment showing CLT total
length (bars; left Y axis) and intracellular CatB activity (line plot;
right Y axis) by HBEC seeded in Matrigel and exposed to DMEM
(B–D), U87MG CM (B), 150 ng/ml IGF-1 (C), or 20 ng/ml VEGF (D) in
the absence or presence of CIBP-4 (20 nM). CatB activity was moni-
tored using Magic Red CatB reagent. Experiments were repeated
four times. F.U., fluorescence units.
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Figure 4. Effects of IBP-4 and CIBP-4 on U87MG anchorage-dependent and anchorage-independent growth. (A) Histogram representing
anchorage-dependent growth of U87MG cells in the absence (gray bars) or presence (hatched bars) of 20 nM IBP-4, 20 nM CIBP-4, or
500 μM dB-cAMP (positive control, black bars) over 6 days. (B–E) Representative images of anchorage-independent growth of U87MG
cells in soft agar in the absence (B) or presence of 20 nM IBP-4 (C), 20 nM CIBP-4 (D), or 500 μM dB-cAMP (E) for 2 weeks. Calibration
bar, 500 μm. (F and G) Histrograms representing quantitative analysis of U87MG cell growth in soft agar by the total covered area per
field (F) and cellularmetabolic activitymeasured by Alamar blue (G). Each bar representsmean cell number per well ± SEM [n=4 (A), n=10
(F), n = 3 (G)]. Asterisks indicate significant (**P < .01 and ***P < .001) differences between DMEM and treatments as determined by
ANOVA followed by either Newman-Keuls multiple comparison test (A) or by Dunnett’s multiple comparison test (F and G).
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CIBP-4 Inhibits CatB Activity In Vitro
The inhibitory capacity of CIBP-4 against the peptidolytic activity
of recombinant CatB was assessed by monitoring the cleavage of the
fluorogenic substrate Z-L-R-AMC immediately after exposure to the
peptide. CIBP-4 induced a concentration-dependent inhibitory effect
on CatB activity ranging from ∼46% (at 0.1 μM) to ∼78% (at both
1 and 10 μM; Figure 3A). The permeable synthetic CatB inhibitor
CA-074 ME was ineffective at 0.1 μM and reduced CatB activity
by ∼13% and ∼73% at 1 and 10 μM, respectively. CIBP-4 was
significantly more potent than CA-074 ME at 0.1 and 1 μM concen-
trations and equally effective at 10 μM (Figure 3A).
Incubation of CIBP-4 with activated CatB did not produce CIBP-4
cleavage products as analyzed by sodium dodecyl sulfate–polyacrylamide
gel electrophoresis (data not shown), thereby excluding the possibil-
ity that CIBP-4 could act as a competitive substrate for the enzyme in
this assay.
CIBP-4 Inhibits CatB Activity Induced in Angiogenic
HBEC in Matrigel
To assess intracellular CatB activity levels in HBEC seeded in
Matrigel and exposed to various growth factors in the absence or
presence of CIBP-4, the cleavage of a membrane permeable CatB
target sequence peptide (Magic Red CatB reagent) was monitored
at the end of the angiogenesis assay.
The levels of intracellular CatB activity in HBEC exposed to
DMEM alone were variable between experiments and did not
consistently correlate with the levels of spontaneous angiogenic
activity (CLT total length) exhibited by the cells (Figure 3, B–D).
U87MG CM, IGF-1, and VEGF, respectively, induced ∼1.9-,
∼7.5-, and ∼2.5-fold increases in HBEC angiogenic response com-
pared to DMEM alone (Figure 3, B–D). This correlated with an
induction of intracellular CatB activity of ∼1.6-fold (U87MG CM),
∼2.7-fold (IGF-1), and ∼7.0-fold (VEGF), respectively, in the treated
cells (Figure 3, B–D). CIBP-4 (20 nM) blocked both the angiogenic
response and the intracellular CatB activity induced by growth factor
treatments (Figure 3, B–D).
IBP-4 and CIBP-4 Inhibit U87MG Cell
Anchorage-Independent Growth
The anchorage-dependent growth of U87MG cells was not affected
by either IBP-4 or CIBP-4 (Figure 4A). The anchorage-independent
growth, measured as the total area per field covered by U87MG
Figure 5. Internalization of recombinant CIBP-4 in HBEC. Confocal microscopy images showing (A and B) internalization of AF647-
conjugated CIBP-4 (red) in HBEC counterstained with 500 nM membrane dye DIOC5(3) (green). HBECs were exposed to 200 nM AF647-
conjugatedCIBP-4 for 30minutes (A) or 150minutes (B) at 37°C. (C andD)Co-localizationof 200nMAF647-conjugatedCIBP-4 (red)with 150nM
LysoTracker (blue) in HBEC after a 2-hour incubation at 37°C. Cells were counterstained with 10 μMMerocyanine (green). Co-localization of
CIBP-4 and LysoTracker appears as pink vesicles. Calibration bar, 25 μm.
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colonies grown in soft agar, was significantly reduced by 20 nM IBP-4
(∼37%), 20 nM CIBP-4 (∼60%), and 500 μM dB-cAMP (∼69%,
positive control), compared to untreated cells (Figure 4, B–F ).
U87MG cell viability, measured by Alamar Blue, was also significantly
reduced by 20 nMIBP-4 (∼25%), 20 nMCIBP-4 (∼74%), and 500 μM
dB-cAMP (∼72%; Figure 4G ). The total number of colonies was
not significantly different between untreated and treated cells (data
not shown).
CIBP-4 Internalizes and Targets Lysosomal-Like
Structures in HBECs
To determine whether CIBP-4 internalizes in HBEC, cells were
exposed to AF647-conjugated CIBP-4 (200 nM) for 150 minutes
at 37°C in DMEM. Internalization of CIBP-4 in HBEC was visual-
ized as early as 30 minutes, with most of the protein located at the
periphery of the cells and in the cell processes (Figure 5A). CIBP-4
internalization increasedwith time (Figure 5,A and B). By 150minutes,
Figure 6. Internalization of recombinant CIBP-4 and its effect on cellular CatB activity in U87MG cells. Confocal microscopy images
showing (A and B) internalization of 200 nM AF647-conjugated CIBP-4 (red) in U87MG cells at 90 minutes (A) or 4 hours (B). Cell were
counterstained with 500 nM membrane dye DIOC5(3) (green). Cellular CatB activity (blue) in U87MG cells (C–H) in the absence (C, D, E,
and G) or presence (F and H) of 200 nM CIBP-4 for 4 hours at 37°C. CatB activity was monitored using Magic Red CatB reagent. Cells
were counterstained with 500 nM DIOC5(3) (green). Calibration bar, 25 μm.
Figure 7. Effects of recombinant CIBP-4 on the growth of U87MG cells grafted on CAM of fertilized eggs. Microphotographs show
U87MG tumors 7 days after cell inoculation. Tumors were treated with either DMSO (vehicle) (A) or 108 ng of CIBP-4 (B) for 4 days.
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CIBP-4 was largely localized in vesicle-like structures with predominant
perinuclear distribution (Figure 5B) as well as along the cellular processes
(Figure 5, C and D). CIBP-4 co-localized (Figure 5, C and D, pink
vesicles) to some extent with the fluorescent acidotropic probe Lyso-
Tracker Yellow that selectively labels acidic organelles in the cells, sug-
gesting that a fraction of the internalized CIBP-4 targets lysosomal-like
structures inHBEC. The remaining fraction of internalizedCIBP-4was
associated with other vesicular structures (Figure 5,C andD, red vesicles)
that likely represent intermediate intracellular trafficking compartments.
CIBP-4 Internalizes in Vesicular-Like Structures and
Reduces CatB Activity in U87MG Cells
AF647-conjugated CIBP-4 internalized in U87MG in a time-
dependent fashion, with a predominant localization in vesicle-like
structures with a perinuclear distribution and along cell processes
(Figure 6, A and B). U87MG cells showed robust CatB activity
throughout the cytoplasm and externalized pericellularly into the
ECM surrounding the plasma membrane (Figure 6, C and D).
Incubation of the cells with 200 nM CIBP-4 for 90 minutes markedly
reduced both pericellular and intracellular CatB activity in U87MG
cells (Figure 6, E–H).
CIBP-4 Inhibits Glioblastoma Tumor Growth in the
Experimental Glioma Assay
The ability of CIBP-4 to block U87MG tumor growth was tested
in an experimental glioma assay using U87MG cells grafted onto the
CAM of fertilized eggs, which form solid and highly vascularized tu-
mors 7 days after inoculation (Figure 7A). Tumors treated with
CIBP-4 (108 ng) for four consecutive days showed significant (P <
.005) size reduction (25%) compared to tumors in the vehicle-treated
group (Figure 7, A and B). However, separation of the tumors into
three size intervals (small, 0–15 mg; medium, 15–20 mg; large, 20–
36 mg) revealed that in the vehicle-treated group, 20% of the tumors
fell in the small size interval, 31.4% in the medium size interval, and
48.6% in the large size interval, while in the CIBP-4–treated group,
52.6% of the tumors fell in the small size interval, 29% in the me-
dium size interval, and 18.4% in the small size interval. These data in-
dicate a 2.6-fold shift (P < .005, Chi-square test) toward smaller size
tumors in the CIBP-4–treated group compared to the vehicle-treated
group (Table 1). The average tumor size in each interval was not sig-
nificantly different between CIBP-4–treated and vehicle-treated groups
(Table 1), confirming no artificial bias in the interval limit selection of
three size groups.
Pharmacokinetics and Biodistribution of CIBP-4 in a
U87MG Xenograft Subcutaneous Tumor Model
The pharmacokinetic profile of CIBP-4 fits well with a biphasic
two-compartmental IV bolus model as calculated using WinNonlin
Pharmacokinetics software package. CIBP-4 exhibited a β circulation
half-life of ∼29.3 minutes (Table 2).
Near-infrared in vivo optical imaging was used to evaluate the
whole body biodistribution of CIBP-4–Cy5.5 in mice-bearing sub-
cutaneous xenograft U87MG-derived tumors. In mice i.v. injected
with CIBP-4–Cy5.5, a rapid accumulation (<0.5 hour) of the protein
was observed in the tumor, reaching a maximum level after 1 hour
(Figure 8A). CIBP-4–Cy5.5 also accumulated in the kidneys, a typical
clearance route for proteins with a molecular weight <60 kDa. After
1 hour, the fluorescence signal decreased rapidly in the body, consistent
with pharmacokinetic profile of the peptide; however, at 24 hours,
detectable levels of CIBP-4–Cy5.5 were still present in the tumor
and kidney regions.
At the end of imaging protocol (24 hours after injection), tumor
sections were analyzed to determine the distribution of CIBP-4–
Cy5.5 within the tumor using fluorescent microscopy (Figure 8,
B–E ). These studies confirmed that the increased tumor optical sig-
nal observed during in vivo imaging resulted from the accumulation
of CIBP-4–Cy5.5 in the subcutaneous tumors.
The fluorescence signal of injected CIBP-4–Cy5.5 was present
throughout the tumor with the exception of the tumor center (Fig-
ure 8B), which often represents a heavily necrotic area with little or no
perfusion. No CIBP-4–Cy5.5 was found in the vasculature 24 hours
after injection (Figure 8C ); however, CIBP-4–Cy5.5 accumulated
around presumably “leaky” vessels and diffused into various areas of
the tumor (Figure 8D). The fluorescent CIBP-4 signal in the tumor
cells appeared predominantly localized in perinuclear vesicles (Fig-
ure 8E ) mirroring the peptide distribution pattern observed in the
in vitro U87MG cellular uptake studies (Figure 6, A and B).
CIBP-4 Inhibited U87MG Tumor Growth in a
Mouse Xenograft Subcutaneous Tumor Model
A subcutaneous U87MG xenograft tumor model in CD-1 nude
mice was used to evaluate the therapeutic efficacy of CIBP-4
(Figure 9A). CIBP-4 (10 mg/kg) administrated i.v. three times per
week resulted in an ∼60% reduction in the tumor size in 80% of
the animals (Figure 9B). Ten percent of the animals showed complete
tumor regression, while another 10% were unresponsive to CIBP-4
(data not shown).
Discussion
IGFBPs are multifunctional proteins that can both positively and
negatively [35] modulate IGF-induced actions [7,36]. Among the
six IGFBPs, IGFBP-4 is the only protein member that has consis-
tently shown to function as a purely inhibitory protein in vitro
and in vivo [8]. These inhibitory actions have been associated with
Table 1. Effects of CIBP-4 on U87MG Tumor Growth in CAM Assay.
Weight Range (mg) 0–15 15–20 20–36
Treatment Vehicle CIBP-4 Vehicle CIBP-4 Vehicle CIBP-4
Number 7 20 11 11 17 7
Average weight (mg) 10.6 ± 2.3 9.9 ± 3.0 16.7 ± 1.2 17.3 ± 1.7 24.1 ± 3.6 25.9 ± 5.7
Frequency (number) and average weight (mg) of U87MG tumors treated with either DMSO (vehicle)
or CIBP-4 (108 ng) in three size groups (small, 0–15 mg; medium, 15–20 mg; large, 20–36 mg).
Table 2. Pharmacokinetic Profile of CIBP-4–Cy5.5.
Parameter Units CIBP-4









Neoplasia Vol. 15, No. 5, 2013 IGFBP-4 Exhibits Anti–Cathepsin B Activity Moreno et al. 563
IGF-dependent and IGF-independent pathways [37]. In a previous
study [10], we identified IGFBP-4 as a protein highly expressed in
dB-cAMP–differentiated U87MG cells and showed that IGFBP-4
exerts very potent anti-angiogenic and anti-tumorigenic effects in
HBECs and glioblastoma cells, respectively. These two actions were
demonstrated to be IGF-independent, although the molecular mecha-
nisms involved are still unknown. Protein sequence analysis indicated
the presence of a Tg1 domain in the C-terminal region of IGFBP-4.
This Tg1 structural motif is also present as a single or repeated se-
quence in a variety of structurally and functionally unrelated proteins,
generically called thyropins, that however share the ability of inhibit-
ing either cysteine or cation-dependent proteinases [13]. Cysteine
Figure 8. (A) In vivo optical images of dorsal whole animal body at various time points (up to 24 hours) after intravenous injection of 100 μg
of Cy5.5-labeled CIBP-4 in a subcutaneous tumor-bearing mouse; ×4 magnification (B), ×20 magnification (C and D), and enlarged ×20
(E) fluorescent microscopic images of mouse subcutaneous brain tumor sections obtained 24 hours after intravenous injection of 100 μg
of CIBP-4–Cy5.5; CIBP-4–Cy5.5 distribution (red), cell nuclei stained by DAPI (blue), and lectin staining of tumor vessels (green).
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cathepsins, particularly CatB, have been shown to be involved in tumor
progression and angiogenesis [38,39]. CatB activity is absent in normal
brain tissue but overexpressed in glioblastomas, especially in areas of
invasion and neovascularization [38,40]. The expression of CatB has
been shown to correlate with the degree of histologic malignancy in
astrocytomas and with shorter survival in patients [40,41].
To identify the mechanism(s) underlying the IGF-independent
anti-angiogenic and anti-tumorigenic activity of IGFBP-4, a C-terminal
IGFBP-4 protein fragment (CIBP-4) containing the Tg1 domain was
recombinantly produced and its capacity to reduce glioblastoma tumor
growth and angiogenesis was tested in vitro. CIBP-4 inhibited the an-
giogenic responses induced by U87MG CM, IGF, and VEGF in
HBECs seeded on Matrigel with similar efficacy to that obtained with
the full-length protein.
Studies using recombinant CatB protein and a fluorogenic Z-L-R-
AMC substrate demonstrated the capacity of CIBP-4 to inhibit CatB
activity in vitro, supporting the hypothesis that proteins bearing a
Tg1 domain in their sequence can act as cysteine proteinase inhibi-
tors. The inhibitory effect of CIBP-4 on CatB activity was even more
potent than that exerted by the synthetic CatB inhibitor CA-074 ME
at low concentrations.
Confocal microscopy studies showed internalization of AF647-
conjugated IGFBP-4 (data not shown) and CIBP-4 in both ECs
and U87MG cells targeting perinuclear lysosomal-like structures,
which suggests its ability to interact with lysosomal proteases, in-
cluding CatB. Similarly, IGFBP-5 uptake into perinuclear vesicular
structures has been reported in mammary epithelial cells [42]. Some
IGFBPs have shown to interact with the cell surface through either
α5β1 integrins through their Arg-Gly-Asp sequence (IGFBP-1) [43],
the type V transforming growth factor β receptor (IGFBP-3) [44], or
ECM proteoglycans through HBDs present in their sequence
(IGFBP2, IGFBP-3, IGFBP-5, and IGFBP-6) [4–6]. However,
IGFBP-4 lacks consensus HBD and has not as yet been demon-
strated to interact with cell membrane surface structures [45]. To
the best of our knowledge, our study is the first to report the ability
of exogenously applied IGFBP-4 and CIBP-4 proteins to access
the intracellular space. This is an important finding and identifica-
tion of the mechanism(s) of CIBP-4 interaction with cell membrane
structures that facilitate its subsequent internalization warrants
further investigation.
The ability of exogenous CIBP-4 to reach lysosomal-like structures
correlated with its capacity to inhibit intracellular CatB in ECs seeded
on Matrigel. During the growth factor–induced capillary-like network
formation, a concomitant increase in intracellular CatB activity was
observed in HBEC undergoing tubulogenesis. These results support
previous in vitro [21,46,47] and in vivo [48,49] studies, indicating that
CatB plays an important role in the process of angiogenesis. Further-
more, both the growth factor–induced angiogenic phenotype and the
intracellular CatB activity in ECs were effectively inhibited by CIBP-4.
During tubulogenesis, degradation of the basement membrane by
proteolytic enzymes has been considered the principal mechanism to
facilitate cell migration, invasion, and capillary tube formation [21].
However, recent studies using quenched fluorescent protein sub-
strates in living cells showed that degradation of ECM protein by
CatB can occur extracellularly and intracellularly in both lysosomal-
like structures and caveolin-1–containing vesicles [21,47]. Moreover,
inhibitors that block both intracellular and extracellular CatB activi-
ties are more effective in reducing angiogenesis in vitro than those
targeting the extracellular CatB fraction alone [21].
Confocal microscopy studies in U87MG cells also demonstrated
that CIBP-4 can internalize into the glioblastoma cells and accumu-
late in perinuclear lysosomal-like structures. CatB activity in U87MG
cells was abundant and highly spread throughout the cell body, with
a large amount of this activity being localized pericellularly and along
the processes. Incubation of U87MG cells with CIBP-4 resulted in a
potent silencing/reduction of both pericellular and intracellular CatB
activities and a significant inhibition of tumor colony formation
in soft agar.
Using an experimental glioma assay, U87MG cells grafted onto
the CAM of fertilized eggs, we demonstrated that ectopic application
of CIBP-4 for 4 days after tumor cell implantation induced a signif-
icant shift toward smaller-sized and less vascularized tumors compared
to the nontreated group.
Biodistribution analysis of Cy5.5-labeled CIBP-4 i.v. injected in
mice-bearing xenograft subcutaneous tumors showed that the protein
reaches and accumulates in the tumor, while it clears rapidly from the
rest of the organs. Histologic evaluation of the tumors indicated that
CIBP-4–Cy5.5 internalizes into glioblastoma cells and targets peri-
nuclear vesicular structures in a similar fashion to that observed in
U87MG cell cultures exposed to CIBP-4.
Figure 9. (A) Schematic representation of the animal protocol used
to evaluate the therapeutic efficacy of CIBP-4 intravenously injected
in CD-1 nude mice-bearing U87MG-derived tumors. (B) Graph repre-
senting the growth of subcutaneously implanted U87MG tumors in
nude mice after intravenous injection of either vehicle (solid line) or
10 mg/kg CIBP-4 (hatched line) three times per week for a period of
23 days.
Neoplasia Vol. 15, No. 5, 2013 IGFBP-4 Exhibits Anti–Cathepsin B Activity Moreno et al. 565
Efficacy studies in this same animal model demonstrated that
CIBP-4 significantly reduces (∼60%) tumor growth when adminis-
trated i.v. at 10 mg/kg, three times per week. This strong inhibition
occurs despite the relatively short half-life (∼20 minutes) of CIBP-4
in circulation, suggesting that strategies to increase its half-life may
enhance the therapeutic effect of the protein.
This study identifies a novel function for IGFBP-4 as a potent
CatB inhibitor and localizes this activity to the C-terminal fragment
of the protein containing a Tg1 domain. It also highlights the ability
of CIBP-4 to block the angiogenic and tumorigenic activity of glio-
blastoma cells both in vitro and in vivo.
Although the proteolytic network that modulates tumor growth
and metastasis involves a large number of protease interactions, CatB
is emerging as one of the most prominent players [50]. CatB is not
only present in tumor cells but also in ECs and macrophages of
primary tumors of the central nervous system (CNS) [23]. Over-
expression of CatB mRNA transcripts and protein has been identified
in human glioma cell lines and biopsy samples and correlates with the
malignant progression of gliomas from astrocytomas to glioblastoma
multiforme [38,51]. Glioblastoma cell invasion can be significantly
inhibited by synthetic inhibitors (K1102, K11017, K11026, K11050,
and E64) that are selective for a high spectrum of cysteine proteases, in-
cluding CatB [52,53], and by inhibitors capable of selectively blocking
both intracellular (Ca074 ME) and extracellular (Ca074) CatB activi-
ties [54,55]. Furthermore, glioblastoma cells transfected with antisense
CatB cDNA exhibit reduced invasion capacity and motility in vitro
[56] and tumor growth invasion in vivo [20,57] compared to the non-
treated cells.
At the vascular level, high expression of CatB has been detected in
ECs of brain tumors [51] and specifically associated with EC prolif-
eration in regions of tumor infiltration into the adjacent normal
brain [58]. Consistent with our findings with CIBP-4, inhibition
of CatB activity has been shown to block CLT formation in Matrigel
[21,48] as well as angiogenesis in animal models [48,49].
The increase in CatB expression at the invasive edge is not limited to
the tumor cells and ECs but is also present in fibroblasts and invading
macrophages [59]. CatB has been detected in macrophages surround-
ing vessels that were located adjacent to necrotic areas [23]. Tumor-
associated macrophages have been extensively studied and shown to
be a major contributor in tumor progression [60] and angiogenesis.
The prominent role of CatB in tumor progression is underscored
by its activation in a variety of cells present within the tumor as well
as by its demonstrated role in multiple tumor-promoting cellular
processes. CatB has been shown to facilitate the dissemination of
cancer cells through degradation of components of the ECM, such
as collagen, laminin, and fibronectin [18]. In addition, it contributes
to the initiation of the proteolytic cascade that involves 1) direct
activation of MMPs such as collagenase-1 and stromelysin [61],
2) activation of the urokinase plasminogen activator/plasminogen
activator/plasmin pathway that ultimately activates latent transform-
ing growth factor–β and MMPs [62], and 3) inactivation of tissue
inhibitors of metalloproteinases (TIMP-1 and TIMP-2), which in
turn enhances the activity of MMPs [63]. Moreover, during proteo-
lytic breakdown of ECMs, some ECM-bound growth factors such as
basic fibroblast growth factor, epidermal growth factor, transforming
growth factor–β, IGF-I, and VEGF may be liberated, thereby promot-
ing growth effects in tumor and stroma cells.
These studies highlight the potential benefit of anti-CatB thera-
pies, including the use of CIBP-4, in reducing tumor progression,
metastasis, and angiogenesis. Evaluation of CIBP-4 efficacy in com-
bination with chemotherapy or radiotherapy may prove useful for the
treatment of tumors in which CatB activity is highly increased, such
a glioblastoma and pancreatic tumors [38,64].
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